William B Feldman
Biographic Data
| ID | 8449761 |
|---|---|
| NAME | William B Feldman |
| GIVEN NAMES | William B |
| FAMILY NAME | Feldman |
| SIGNATURE | FELDMAN W B |
| AFFILIATIONS | Brigham and Women's Hospital |
| ORCID | 0000-0003-3467-5869 |
| VERIFIED | Yes |
| TOTAL WORKS | 10 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 10 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Tertiary Patents on Drugs Approved by the FDA
The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion
Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare
This study compares the revenues earned by manufacturers 9 vs 13 years following US Food and Drug Administration approval for negotiation-eligible products from 2012 to 2022
Use of Track One Prioritized Examination for Pharmaceutical Patents
This study examines the use of the Track One prioritized patent examination program by pharmaceutical manufacturers from 2011 to 2022
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines
The Covid‐19 pandemic highlighted the need to examine public trust in the U.S. Food and Drug Administration (FDA) vaccine approval process and the role of political influence in the FDA's decisions. Ensuring that the FDA is itself trustworthy is important for justifying public trust in its actions, like vaccine approvals, thereby promoting public health. We propose five conditions of trustworthiness that the FDA should meet when it reviews vaccin…
Outcomes of the 340B Drug Pricing Program
In this scoping review of the 340B program, we found that the 340B program was associated with financial benefits for hospitals, clinics, and pharmacies; improved access to health care services for patients; and substantial costs to manufacturers. Increased transparency regarding the use of 340B program revenue and strengthened rulemaking and enforcement authority for the Health Resources and Services Administration would support compliance and h…
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022
In this cross-sectional study, simulating the drug price negotiation provisions in the Inflation Reduction Act of 2022 revealed important limitations, including strict selection criteria and the potential for drugs to become ineligible for negotiation during the 2 years between selection and prices taking effect. Despite these limitations, the policy still delivered substantial savings because ceiling prices offered steep discounts, in part, by e…
Practicalities of Impracticability
Impracticability is an ethical standard for waiver of informed consent in research. We examine how well the criterion of impracticability appears to have been fulfilled in a set of 36 completed randomized controlled trials (RCTs) that secured consent from some subjects or LARs and employed waivers to enroll others. These trials were identified among 155 RCTs using waivers of consent in a convenience sample drawn from 7 systematic reviews. Recruit…
Association Between USMLE Step 1 Scores and In-Training Examination Performance
PURPOSE: On February 12, 2020, the sponsors of the United States Medical Licensing Examination announced that Step 1 will transition to pass/fail scoring in 2022. Step 1 performance has historically carried substantial weight in the evaluation of residency applicants and as a predictor of subsequent subject-specific medical knowledge. Using a systematic review and meta-analysis, the authors sought to determine the association between Step 1 score…
Medicare Spending on Drugs With Accelerated Approval, 2015-2019
This article examines the budgetary implications of high-priced accelerated approval drugs by estimating Medicare spending on these drugs from 2015 through 2019
Estimating Rebates and Other Discounts Received by Medicare Part D
Models that fail to properly account for increasing rebates and other discounts will overestimate Medicare Part D expenditures. Rigorous and transparent methods for estimating discounts are critical for understanding patterns in spending and developing new cost-containment strategies
No prominent works on this page.
Association Between USMLE Step 1 Scores and In-Training Examination Performance
PURPOSE: On February 12, 2020, the sponsors of the United States Medical Licensing Examination announced that Step 1 will transition to pass/fail scoring in 2022. Step 1 performance has historically carried substantial weight in the evaluation of residency applicants and as a predictor of subsequent subject-specific medical knowledge. Using a systematic review and meta-analysis, the authors sought to determine the association between Step 1 score…
Medicare Spending on Drugs With Accelerated Approval, 2015-2019
This article examines the budgetary implications of high-priced accelerated approval drugs by estimating Medicare spending on these drugs from 2015 through 2019
Estimating Rebates and Other Discounts Received by Medicare Part D
Models that fail to properly account for increasing rebates and other discounts will overestimate Medicare Part D expenditures. Rigorous and transparent methods for estimating discounts are critical for understanding patterns in spending and developing new cost-containment strategies
Practicalities of Impracticability
Impracticability is an ethical standard for waiver of informed consent in research. We examine how well the criterion of impracticability appears to have been fulfilled in a set of 36 completed randomized controlled trials (RCTs) that secured consent from some subjects or LARs and employed waivers to enroll others. These trials were identified among 155 RCTs using waivers of consent in a convenience sample drawn from 7 systematic reviews. Recruit…
Securing the Trustworthiness of the FDA to Build Public Trust in Vaccines
The Covid‐19 pandemic highlighted the need to examine public trust in the U.S. Food and Drug Administration (FDA) vaccine approval process and the role of political influence in the FDA's decisions. Ensuring that the FDA is itself trustworthy is important for justifying public trust in its actions, like vaccine approvals, thereby promoting public health. We propose five conditions of trustworthiness that the FDA should meet when it reviews vaccin…
Outcomes of the 340B Drug Pricing Program
In this scoping review of the 340B program, we found that the 340B program was associated with financial benefits for hospitals, clinics, and pharmacies; improved access to health care services for patients; and substantial costs to manufacturers. Increased transparency regarding the use of 340B program revenue and strengthened rulemaking and enforcement authority for the Health Resources and Services Administration would support compliance and h…
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022
In this cross-sectional study, simulating the drug price negotiation provisions in the Inflation Reduction Act of 2022 revealed important limitations, including strict selection criteria and the potential for drugs to become ineligible for negotiation during the 2 years between selection and prices taking effect. Despite these limitations, the policy still delivered substantial savings because ceiling prices offered steep discounts, in part, by e…
Use of Track One Prioritized Examination for Pharmaceutical Patents
This study examines the use of the Track One prioritized patent examination program by pharmaceutical manufacturers from 2011 to 2022
Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare
This study compares the revenues earned by manufacturers 9 vs 13 years following US Food and Drug Administration approval for negotiation-eligible products from 2012 to 2022
Tertiary Patents on Drugs Approved by the FDA
The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion
Medicine (7 works) · Business (6 works) · Health Systems, Economic Evaluations, Quality of Life (6 works) · Pharmaceutical Economics and Policy (5 works) · Actuarial science (4 works) · Law (4 works) · Medicare Part D (4 works) · Political science (4 works) · Computer Science (3 works) · Health care (3 works)